Trials / Completed
CompletedNCT03818308
Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir
Multicenter Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir Fix Dose combination_The HepNet Acute HCV-V Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Hannover Medical School · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm multicenter pilot study to evaluate the efficacy and safety of treatment with sofosbuvir (SOF)/velpatasvir (VEL) fix dose combination (FDC) in patients with acute hepatitis C virus (HCV) infection.
Detailed description
This is a single arm multicenter pilot study to evaluate the efficacy and safety of treatment with SOF/VEL FDC for 8 weeks in patients with acute HCV infection as measured by the proportion of subjects with sustained viral response (undetectable HCV RNA) 12 weeks after stop of therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sofosbuvir and Velpatasvir | All subjects will receive one film-coated tablet of sofosbuvir/velpatasvir (400/100 mg) orally once daily for 8 weeks. |
Timeline
- Start date
- 2019-05-28
- Primary completion
- 2021-06-08
- Completion
- 2021-06-08
- First posted
- 2019-01-28
- Last updated
- 2021-07-06
Locations
14 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT03818308. Inclusion in this directory is not an endorsement.